Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine

Tutkimustuotos: ArticleScientificvertaisarvioitu

1 Lataukset (Pure)

Abstrakti

Metabolic syndrome and related cardiovascular risk factors are well-known comorbidities among patients with schizophrenia. Biomarkers of these antipsychotic-associated metabolic adverse effects and antipsychotic-induced weight gain are needed. Glucagon-like peptide-1 (GLP-1) is involved in insulin secretion, regulation of satiety, inhibition of food intake, and inhibition of gastric emptying. GLP-1 also induces reduction in body weight. Visfatin/ NAMPT/ PBEF is an adipocytokine secreted by several cells and tissues. Increased plasma visfatin levels have been associated with overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases, low grade inflammation, and proinflammatory markers. Associations between antipsychotic-induced weight gain and serum visfatin and GLP-1 levels have been little studied in patients with schizophrenia. The aim of the present study was to test the possible role of serum GLP-1 and visfatin level alterations as markers of weight gain in association with metabolic and inflammatory markers in 190 patients (109 male, 81 female) with schizophrenia on clozapine treatment. High serum levels of GLP-1 correlated significantly with higher levels of visfatin, leptin, insulin, HOMA-IR, higher BMI, and weight change among men. Associations between serum visfatin levels and BMI or weight change were not found in the present patients. Serum GLP-1 level seems to be a marker of metabolic risk factors among men with schizophrenia on clozapine treatment. Female patients may be more sensitive to suppressive effects of clozapine on GLP-1 secretion. Patients on clozapine would benefit from GLP-1 agonists as preventive treatment.

AlkuperäiskieliEnglanti
Artikkeli114227
JulkaisuPSYCHIATRY RESEARCH
Vuosikerta306
DOI - pysyväislinkit
TilaJulkaistu - jouluk. 2021
OKM-julkaisutyyppiA1 Alkuperäisartikkeli

Julkaisufoorumi-taso

  • Jufo-taso 1

!!ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Sormenjälki

Sukella tutkimusaiheisiin 'Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.

Siteeraa tätä